Organovo (NASDAQ:ONVO) Coverage Initiated at

Research analysts at started coverage on shares of Organovo (NASDAQ:ONVOGet Rating) in a research note issued to investors on Saturday. The firm set a “sell” rating on the medical research company’s stock.

Organovo Stock Up 5.0 %

Organovo stock opened at $2.52 on Friday. Organovo has a twelve month low of $1.71 and a twelve month high of $7.90. The company has a 50 day moving average of $2.80 and a 200-day moving average of $2.89. The stock has a market capitalization of $21.95 million, a PE ratio of -1.81 and a beta of 1.14.

Organovo (NASDAQ:ONVOGet Rating) last announced its earnings results on Thursday, August 11th. The medical research company reported ($0.37) EPS for the quarter.

About Organovo

(Get Rating)

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

See Also

Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with's FREE daily email newsletter.